Darapladib
Darapladib is an inhibitor lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis. It was discovered by Human Genome Sciences in collaboration with GlaxoSmithKline (GSK).
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Darapladib
Darapladib is an inhibitor lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis. It was discovered by Human Genome Sciences in collaboration with GlaxoSmithKline (GSK).
has abstract
Darapladib is an inhibitor lip ...... ed with standard medical care.
@en
CAS number
356057-34-6
ChEMBL
FDA UNII code
UI1U1MYH09
KEGG
PubChem
Wikipage page ID
19,684,498
page length (characters) of wiki page
Wikipage revision ID
984,350,626
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
ChEMBL
ChemSpiderID
IUPAC name
N--2-[2-[methylsulfanyl]-4-oxo ...... phenyl]phenyl]methyl]acetamide
@en
IUPHAR ligand
KEGG
D03650
@en
legal status
Investigational
@en
PDB ligand
PubChem
routes of administration
SMILES
FCc1cccc2cccCNCCNCC
@en
StdInChIKey
WDPFJWLDPVQCAJ-UHFFFAOYSA-N
@en
synonyms
SB-480848
@en
UNII
UI1U1MYH09
@en
Verifiedfields
changed
@en
verifiedrevid
443,580,789
Watchedfields
changed
@en
wikiPageUsesTemplate
subject
hypernym
comment
Darapladib is an inhibitor lip ...... on with GlaxoSmithKline (GSK).
@en
label
Darapladib
@en